Gary S Elliott

US Patent:

6399590, Jun 4, 2002

Filed:

Aug 10, 2001

Appl. No.:

09/927246

Inventors:

Gary T. Elliott - Stevensville MT
Patricia A. Weber - Hamilton MT
C. Gregory Sowell - Hamilton MT

Assignee:

Corixa Corporation - Seattle WA

International Classification:

A61K 31715

US Classification:

514 53, 536 53, 536 55, 536 551, 53612313

Abstract:

The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2-Deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-2-[(R)-3-octadecanoyloxytetradecanoylamino]-- -glucopyranosyl]-2-[(R)-3-hexadecanoyloxytetradecanoylamino]- -glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.

US Patent:

6699846, Mar 2, 2004

Filed:

Mar 14, 2001

Appl. No.:

09/808669

Inventors:

Gary T. Elliott - Stevensville MT
David Johnson - Hamilton MT
Patricia Weber - Stevensville MT
Greg Sowell - Bothell WA

Assignee:

Corixa Corporation - Seattle WA

International Classification:

A61K 31715

US Classification:

514 53, 514 54, 514175, 536 53, 536 55, 536 551, 53612313

Abstract:

Methods for treating diseases or conditions modulated or ameliorated by nitric oxide, particularly ischemia and reperfusion injury, are provided, using glycolipids structurally related to monophosphoryl lipid A but with notable reduction in proinflammatory and pyrogenic activity.

US Patent:

60136405, Jan 11, 2000

Filed:

Aug 21, 1998

Appl. No.:

9/138305

Inventors:

Gary T. Elliott - Stevensville MT
Patricia A. Weber - Hamilton MT
C. Gregory Sowell - Hamilton MT

Assignee:

Ribi ImmunoChem Research, Inc. - Hamilton MT

International Classification:

A61K 31715
C08B 3700

US Classification:

514 53

Abstract:

The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2-Deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoy l]-2-[(R)-3-octadecanoyloxytetradecanoylamino]-. beta. -D-glucopyranosyl]-2-[ (R)-3-hexadecanoyloxytetradecanoylamino]-D-glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.

US Patent:

20160207869, Jul 21, 2016

Filed:

Aug 28, 2015

Appl. No.:

14/839810

Inventors:

- San Diego CA, US
Ernst FREUND - Erlinsbach, CH
Oliver SCHLÖRKE - Oberwil, CH
Joerg LILL - Aarau, CH
Lars ROGALL - Aarau, CH
Dario MENIA - Aarau, CH
Gary ELLIOTT - Portland OR, US
James PATERNITI - San Diego CA, US

International Classification:

C07C 62/32
C07H 15/24

Abstract:

A cardiogenin major isomer is obtained from a methanol extract of and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).